22:09 , Aug 8, 2019 |  BC Innovations  |  Distillery Techniques

Mice with wild microbiomes predict clinical results

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: Animal models NIH's National Institute of Diabetes and Digestive and Kidney Diseases created a laboratory mouse model with a wild microbiome that could yield better predictions of clinical results than...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
14:35 , Apr 1, 2019 |  BC Extra  |  Clinical News

MSKCC CAR T shows 72% response in mesothelioma

Researchers from MSKCC presented data for a mesothelin-targeted autologous CAR T cell therapy that could be the first to crack the solid tumor juggernaut for this treatment modality while also minimizing toxicity. The data could...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
18:17 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
00:11 , Jan 8, 2019 |  BC Extra  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
18:00 , Nov 9, 2018 |  BC Week In Review  |  Company News

OSE regains rights to FR104 from J&J

OSE Immunotherapeutics S.A. (Euronext:OSE) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) will return to OSE worldwide rights to FR104. The compound has completed a Phase I trial to treat rheumatoid arthritis;...